AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05253599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: They performed these exercises 10-15 reps/day for 5 days per week for 4 weeks. Stretching was focused on each muscle group for 3 repetitions for 10 seconds per muscle group (Hamstring, Hip flexors and Lumbar Extensors).7 A home-based exercise protocol was prescribed to all the subjects to perform at home. All the subjects in three groups were undergone hot pack therapy for 20 mins and ultrasound with a frequency of 1 Mhz and intensity of 1.5 W/cm2 in continuous form for five minutes.
Study NCT01936467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard technique EUS-FNA
Description: Standard suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
Study NCT01936467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capillary suction technique for EUS FNA
Description: Capillary suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously
Study NCT04034849 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation whit Low-Level Laser Therapy
Study NCT04034849 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Device turned off
Study NCT04129476 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cooperative Education Program based on Precede-Proceed Model
Description: The study population is pregnant women in Gonabad city between 30 and 35 weeks of gestation. In the experimental group, the training program was based on the PRECEDE-PROCEDURE model, including training on anatomy and prenatal physiology, prenatal and postnatal care, prenatal and postnatal mental health, as well as prenatal and postnatal events, and Mothers' feelings and attitudes, as well as postpartum problems and strategies will be discussed. The training period is 60 minutes in 4 consecutive sessions. Predisposing, reinforcing and enabling factors inventory, General health questionnaire (GHQ), Edinburgh depression inventory Will be filled Before the intervention, immediately after the intervention and 4 to 6 weeks after the intervention.
Study NCT04041973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: One tablet AL contains 20 mg artemether and 120 mg lumefantrine~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest.
Study NCT04041973 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: One tablet contains Vitamin-A : 5000 USP units, Vitamin D: 400 USP Units, Ascorbic acid: 75 mg, Thiamine Mononitrate: 2 mg, Riboflavin: 3 mg, Niacin amide: 20 mg.~The prophylaxis will start with a 3-day course of twice daily AL. This will be followed by 2 doses 8 hours apart on one day per week for up to 3 28-35 day consecutive follow-up periods and for 4 weeks after leaving the forest.
Study NCT03659331 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc
Description: blood tests will be performed: GGT SGOT, SGPT, LDH, A.P. Direct and indirect bilirubin, blood proteins, cholesterol, P.T. and a complete blood count.
Study NCT02498262 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality System
Description: The participants will use a virtual reality system that is like a large video game and complete some job skill tasks in the virtual world video game.
Study NCT02901847 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PAD tailored care
Description: PAD tailored care
Study NCT00552864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
Study NCT00552864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: 0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
Study NCT03302390 — intervention group
Intervention type: PROCEDURE
Intervention: Shave Biopsy of Psoriasis Lesion
Description: The investigator will take about 0.5x0.5 inch square section of skin from the psoriasis lesion. To numb the skin, the subject will receive a small injection of 0.5% lidocaine HCl 5mg/mL with 1:200,000 mcg/mL epinephrine solution as per standard shave biopsy protocol. The shaving instrument has a blade that will shave off a superficial piece of skin that is less than \<3mm in thickness. After 14 days, the subject will return to make sure that the skin biopsy site has healed properly. The piece of skin that is removed will be grafted onto the back of an immunocompromised SCID mouse. An approved IACUC protocol covering this procedure will be in place prior to engraftment.
Study NCT00723749 — intervention group
Intervention type: DRUG
Intervention: Buprenorphine/Naloxone
Description: Sublingual combination tablet containing buprenorphine and naloxone at a ration of 4:1, respectively. It is available in two tablet strengths: 2 mg buprenorphine \& 0.5 mg naloxone and 8 mg buprenorphine \& 2 mg naloxone.~The only effective and safe use is sublingual administration. SUBOXONE® use will occur on the basis of SPC and is solely aimed at medical-therapeutic necessity.
Study NCT02039895 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HITS
Description: Helical irradiation of the total skin by helical tomotherapy
Study NCT00989547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Blood VITA 34
Description: Intervention type: Autologous Umbilical Cord Blood Transfusion
Study NCT04669769 — intervention group
Intervention type: OTHER
Intervention: interview
Description: telephone interview
Study NCT02694042 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mission is Remission®
Description: A web-based teaching a support program for adolescents living with inflammatory bowel disease (IBD).
Study NCT02623998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Dose is titrated to achieve fasting normoglycemia
Study NCT02623998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin/metformin
Description: Dose is titrated to 50/1000 mg bid or maximal tolerated dose
Study NCT02623998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle therapy
Description: Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
Study NCT01337362 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin clamp
Description: Patients will be exposed to low bloodsugar
Study NCT01337362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insulin clamp
Description: Patients will be exposed to low bloodsugar
Study NCT00851565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Measurement of serum infliximab and anti-infliximab antibodies
Description: In the intervention group treatment of patients with Crohn's disease with secondary loss of response to infliximab is based on serum infliximab and anti-infliximab Ab levels according to following algorithm:~1. Low s-infliximab in the presence of anti-infliximab Ab: Adalimumab 80 mg s.c. followed by 40 mg every 2 weeks.~2. Low s-infliximab without anti-infliximab Ab: Infliximab 10 mg/kg i.v. every 8 weeks.~3. High s-infliximab without anti-infliximab Ab: Stop infliximab treatment. Review history. Steroids or surgery.~4. High s-infliximab in the presence of anti-infliximab Ab: Same as number 3.
Study NCT00851565 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status
Description: In the control group patients with Crohn's disease with secondary loss of response to infliximab is treated according to current standard of care which is to increase dose of infliximab to 5 mg/kg every 4 weeks without knowledge of serum infliximab levels and anti-infliximab Ab status.
Study NCT04413422 — intervention group
Intervention type: DRUG
Intervention: type of hypnotic used for induction of general anesthesia
Study NCT01857336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infusion of G-CSF mobilized peripheral harvest
Study NCT02747888 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: •Referral to Genetic Counselor, if indicated
Study NCT03344068 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Intensity Modulated Radiation Therapy, Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
Study NCT03344068 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Intensity Modulated Radiation Therapy, Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
Study NCT03344068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Nedaplatin 80mg/m2 d1+5-fluouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
Study NCT03344068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Nedaplatin 80mg/m2 d1+5-fluouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
Study NCT03344068 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutren® Optimum
Description: Nutren® Optimum, 7 scoops each time, three times a day, at begin of radiotherapy
Study NCT03404544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin bolus
Description: Carbetocin 100 mcg intravenous as a bolus (less than 2 sec)
Study NCT03404544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin infusion
Description: Carbetocin 100 mcg intravenous as a 10 minutes infusion
Study NCT00208455 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DePuy Proxima™ Hip
Description: A short, anatomic, cementless femoral component for use in total hip arthroplasty
Study NCT00402051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles
Study NCT00402051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2, intravenous (IV), every 21 days x 6 cycles
Study NCT00402051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under the concentration curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
Study NCT01521247 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Asthma Transition Program
Description: Asthma Education.
Study NCT03617835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R - Low dose of BI 655130
Description: Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the periumbilical region following an overnight fast of at least 10 hours.
Study NCT03617835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T1 - Low dose of BI 655130
Description: Single low dose of BI 655130 administered as two single subcutaneous injections (given as 2 x 1 milliliter (mL)) in the periumbilical region (left and right) following an overnight fast of at least 10 hours.
Study NCT03617835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2 - Low dose of BI 655130
Description: Single low dose of BI 655130 administered as one single subcutaneous injection (given as 1 x 2 milliliter (mL)) in the thigh region following an overnight fast of at least 10 hours.
Study NCT03617835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T3 - High dose of BI 655130
Description: Single high dose of BI 655130 administered as two single subcutaneous injections (given as 2 x 2 milliliter (mL)) in the periumbilical region (left and right) following an overnight fast of at least 10 hours.
Study NCT01191008 — intervention group
Intervention type: DRUG
Intervention: Latanoprost-timolol maleate fixed combination ophthalmic solution
Description: Xalacom® Combination Eye Drops depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. One drop should be applied to the affected eye(s) once daily.
Study NCT00978562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DCE-MRI
Study NCT00978562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Description: Undergo DSC-MRI
Study NCT00978562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol Non-Stoichiometric Magnetite
Description: Given IV
Study NCT00978562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Description: Given IV
Study NCT03060018 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentec (SenTec) Digital Monitoring System with OxiVenT Sensor
Description: The sensor will be attached to four anatomical positions (thoracic left and right; abdominal left and right), starting with the left thoracic position followed by 4-hourly clockwise position rotation. In case of severe oedema, the ear lobes will be used as anatomical measurement sites and changes to the contralateral ear lobe are made every 4 hours.
Study NCT03694977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCS110/PDR001 combination
Description: MCS110 7.5mg/kg iv since 1st cycle PDR001 300 mg iv since 2nd cycle Q 3weeks
Study NCT04160377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine was assigned to be the treatment for the depression patients with melancholic features or not .
Study NCT01948076 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: resident with GE vscan
Description: resident with GE vscan
Study NCT02755129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Walking Exercises-Six Minute Walk (6MW) Test
Description: The Six Minute Walk (6MW) Test measures the distance an individual is able to walk over a total of six minutes on a flat surface. The goal is for the individual to walk as far as possible in six minutes. The Six Minute Walk (6MW) test will be performed within the Computer Assisted Rehabilitation Environment (CAREN) system system environment - single arm
Study NCT02755129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Walking Exercises-4 Meter Gait Speed (4MGS) Test
Description: The 4 Meter Gait Speed (4MGS) Test measures the gait speed an individual is able to walk over 4 meters on a flat surface. The goal is for the individual to walk as fast as possible over 4 meters.~It will be repeated 3 times within the aforementioned 6MW test (after approximately 1, 3 and 5 minutes) to get variability due to subject tiredness. The test will be performed within the CAREN system environment. - single arm
Study NCT02755129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Walking Exercises-Five Times Sit to Stand (FTSTS) Test
Description: The Five Times Sit to Stand (FTSTS) Test measures the time a subject takes to stand up from an armchair 5 times in a row, without stopping in between. It is a short test which measures dynamic balance and functional mobility - single arm
Study NCT02755129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Walking Exercises-Expanded Timed Get-Up-and-Go (ETGUG) Test
Description: The Expanded Timed Get-Up-and-Go (ETGUG) Test measures the time it takes a subject to stand up from an armchair, walk a distance of 10 m, turn, walk back to the chair, and sit down. It is a short test of basic mobility skills for frail community-dwelling elderly. - single arm
Study NCT02755129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reveal LINQ accelerometer
Description: Walking exercises test
Study NCT02755129 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 3D accelerometer
Description: Walking exercises test
Study NCT00356811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib oral tablets
Description: Lapatinib will be given as tablets contain 410 mg of lapatinib ditosylate monohydrate, equivalent to 250 mg lapatinib free base per tablet. Subjects will be given a 4 week supply of lapatinib tables and instructed to take 6 tablets daily (1500 mg daily dose) orally at the same time each day. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
Study NCT00356811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel infusion
Description: Subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle). Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
Study NCT01022411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brown rice/White rice
Description: ad libitum intake of brown rice/white rice at every lunch and dinner for 16 weeks
Study NCT01022411 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Brown rice/White rice
Description: ad libitum intake of brown rice/white rice at every lunch and dinner for 16 weeks
Study NCT03496376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: The material used for thoracic kinesio taping application was Kinesio® Tex Gold™ (Kinesio Holding. Patients were instructed to sit upright on an armless chair with no back support, with knees flexed to 90 degrees, feet on the floor and arms relaxed. Kinesio tape was applied anteriorly and posteriorly to facilitate respiratory muscles (primarily diaphragm) along the subcostal area. Additionally, two more kinesio tapes were applied to upper trapezius and scalene muscles' area which lies between neck and acromion at both sides (left and right).
Study NCT03496376 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep Breathing Exercises
Description: Three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
Study NCT03496376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deep Breathing Exercises
Description: Three different deep breathing exercises (diaphragmatic, thoracic, and lateral basal), each consisting of three sets of 10 repetitions, with 30 seconds of rest between each set.
Study NCT02466347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Description: Inhaled corticosteroid, pMDI
Study NCT02466347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: Inhaled corticosteroid, pMDI
Study NCT02466347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol (as xinafoate)
Description: Long Acting Beta-agonist (LABA), pMDI
Study NCT02466347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol (as xinafoate)
Description: Long Acting Beta-agonist (LABA), pMDI
Study NCT05841589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Green tea extract mouth rinse
Description: herbal extracts mouth rinse that was prepared in the microbiology laboratory
Study NCT05841589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Garlic with lime extract mouth rinse
Description: herbal extracts mouth rinse that was prepared in the microbiology laboratory
Study NCT05841589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pomegranate extract mouth rinse
Description: herbal extracts mouth rinse that was prepared in the microbiology laboratory
Study NCT05841589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth rinse
Description: herbal extracts mouth rinse that was prepared in the microbiology laboratory
Study NCT01744704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 0.5 µg/mL Sentinel
Description: In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level
Study NCT01744704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 5 µg/mL Sentinel
Description: Part 0 represented a sentinel group.
Study NCT01744704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF 20 µg/mL Sentinel
Description: In Part 0, all subjects received one 35-μL drop of rh-NGF at an appropriate concentration in the study eye (right or left) according to the randomisation list to achieve the required dose level